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This work introduces a new dimension for controlled drug delivery by nanofiber based 
scaffolds for anticancer therapy. The model anticancer drugs adapted in this work are curcumin 
and 5-fluorouracil (5-FU). Most of the drug loaded nanofibers synthesized thus far have failed 
to address the needs of personalized medication due to poor scalability of drug loading and 
delivery kinetics. This work opens up new avenues for circumventing such complications by 
altering the drug release profile by simple one-step crosslinking reaction. With an aim to 
emphasize upon the role of polymer crosslinking on drug release kinetics, two variations of 
dual drug loaded core-shell nanofibers were synthesized with different extent of crosslinking 
and polymer composition. These two variations of drug loaded nanofibers exhibited 
contrasting 5-FU release profile and thus manifested different therapeutic efficacy at different 
time points against A549 (Non-Small Cell Lung cancer) cells. The drug release profile of these 
fibers was further corroborated with different kinetic models to gain a perspective on the 
underlying mechanism driving the drug release from type I and type II nanofibers. The 
synergistic therapeutic potential of curcumin and 5-FU loaded core-shell nanofibers (type I and 
type II nanofibers) was also validated against A549 cells. As an outcome of this work, a clear 
correlation of cell viability with time lag in drug delivery in the case of type I and type II 
nanofibers could be drawn, which makes nanofiber based drug delivery even more flexible and 
therapeutically effective with minimal side effects.  
 
1. Introduction 
Electrospinning is a versatile and cost effective means of 
fabricating polymeric nanofibers. Ever since its inception it has 
evolved to confer diverse nanostructures and microstructures to 
wide range of polymers[1]. These polymeric nanofibers have 
already established their share of success in the field of 
filtration, tissue engineering, textile industry, pharmaceutics 
and electronics[2]. Such polymeric biodegradable scaffolds at 
the nanoscale act as an excellent interface to blend-in the 
difference between the biomaterials and biological components 
as they closely mimic the extracellular matrix of in-vivo system. 
Since long past such biocompatible polymeric nanofibers have 
witnessed extensive application in the field of tissue 
engineering[3]. The electrospinning technique as such enables 
uniform incorporation of bioactive molecules and nanoparticles 
in the nanofiberous polymeric matrix. Nanofibers by virtue of 
being at the nanoscale have large surface area to volume ratio 
and thus significant fraction of drugs loaded in these nanofibers 
are held on the nanofiber surface by weak physical forces. It is 
these loosely adsorbed drug molecules on the nanofiber surface 
that account for brief burst release of drug in the initial phase of 
drug release study[4]. As most of the nanofiber based 
anticancer drug delivery systems are associated with such burst 
release phase, they do not meet the basic criteria of providing a 
controlled and sustained drug release profile. An alternative 
approach to overcome such issues would be to introduce a 
diffusion barrier between the drugs loaded polymer phase and 
simulated release medium. In this case, the drug molecules 
would have to permeate across the passive barrier by diffusion 
to arrive at the release medium. This additional passive and 
permissive barrier regulates the drug release kinetics at an 
additional level. With this as the basis, in this work core–shell 
nanofiber with anticancer drug loaded core and a cross-linked 
shell barrier has been sought as a controlled and sustained drug 
delivery system for treatment of lung cancer. 
Lung cancer is the second most prominently diagnosed cancer 
in the world[5]. A number of anticancer drugs have been 
evaluated for their efficacy against lung cancer. A major 
problem associated with such drugs is their therapeutic 
efficacy, drug resistance, specificity, bioavailability, bystander 
effects and the availability of suitable therapeutic formulation 
for appropriate means of administration. In this work, major 
emphases is being laid on attaining better therapeutic efficacy 
at lower drug dosages by using a combination of drugs with 
synergistic effects and at the same time improve their 
bioavailability by employing a nanofiber based drug delivery 
scaffold[6]. Such a system would aid to circumvent the 
problems associated with patient’s predisposal to higher drug 
dosage levels and thereby ameliorate the health of the patient 
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Pre-existing literature strongly supports the synergistic 
anticancer efficacy of curcumin and 5-FU, and the cellular 
signaling pathways by means of which they attain this 
synergism have also been elucidated in the past[7]. 5-FU 
mediates its antineoplastic effects by inhibiting the activity of 
thymidine synthetase (TS) enzyme which otherwise actively 
participates in metabolic reactions involved in nucleic acid 
synthesis (RNA and DNA). Owing to TS inactivation by 5-FU, 
the cellular nucleic acid composition is altered, which further 
leads to mis-incorporation of bases and the multiple lethal  
mutations that arise because of this, effectuates cell death.  A 
major drawback associated with 5-FU as chemotherapeutic 
agent is its short life time and its catabolism in liver by an 
enzyme called dihydro pyrimidine dehydrogenase (DPD). As 
high as 80% of 5-FU administered is primarily in-effectuated 
by catabolic reactions in liver[8].  
The plant polyphenol, curcumin being loaded in the shell of the 
nanofibers is released in the initial phase and sensitizes the 
cancer cells for 5-FU anticancer activity. In addition to this, 
curcumin has been found to down-regulate growth factor 
receptor expression in cancer stem cell which counteracts the 
chances of cancer recurrence after 5-FU chemotherapy [9]. 
With the above mentioned convictions as the basis, in this work 
we fabricate core-shell nanofibers loaded with 5-FU and 
curcumin in core and shell of the nanofibers, respectively.   
Apart from this, an attempt has been made to independently 
fine tune the release profile of drugs loaded in core and shell of 
nanofibers in order to meet the needs of personalized cancer 
medication. This controlled and sustained drug release is 
attained by two critical fabrication steps, one by altering the 
crosslinking time and the other by altering the core polymer 
composition.  In principle, by both means stated above, the 
dissolution of the polymer in hydrophilic environment is altered 
so as to attain a favorable drug release profile.  
 
2. Results and discussion 
2.1 Characterization of core-shell morphology of nanofibers 
The FE-SEM micrographs of drug loaded type I and type II 
PEO-PEI nanofibers (Fig 2) revealed that both type I and type 
II core-shell nanofibers were of uniform diameter of 103 ±13 
nm and 119 ±14.97 nm, respectively. 
  
There were no significant difference in overall fiber 
morphology of type I and type II nanofibers. Owing to 
difference in core and shell polymer composition of type II 
nanofibers, core shell morphology was clearly discernable 
under FE-SEM as compared to that of type I nanofibers (Fig 
2(c)&(d)). The surfaces of both the fibers were irregular to 
certain extent due to higher polymer concentration in the shell 
solution. The difference in PEO weight percentage in core and 
shell solution was adapted in order to retain the core and shell 
layers intact in the polymeric droplet at the needle tip and also 
to provide sufficient viscous drag to the core solution so as to 
maintain the core-shell morphology throughout the process of 
nanofiber extrusion, stretching and whipping. As observed in 
FE-SEM images of nanofibers, the core of the fibers was 
smooth and of uniform diameter throughout i.e. ~ 45 nm for 




Fig. 2 FE-SEM images of Type II core-shell nanofibers (a), (c) 
and Type I core-shell nanofibers (b), (d) with insets showing 
mean fiber diameter and fiber diameter distribution. 
 
To further confirm the core-shell structure the PEO core of type 
II PEO-PEI core-shell nanofibers was extracted in water and 
observed by TEM (Fig 3(b)). The contrast of nearly hollow 
core of PEO extracted nanofiber clearly established the 
presence of intact and distinct 5-FU loaded PEO core 
Fig. 1 Schematic outline of (a) Drug loaded PEO- PEI core-shell nanofibers fabrication by co-axial electrospinning and their 
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throughout the core-shell nanofibers. After 24 hours incubation 
in release medium (PBS) a considerable increase in nanofiber 
diameter (i.e. from 126±9 nm to  223±12 nm) could be 
observed due to water permeation and retention (Fig3 (c)&(d)). 
The concentricity of core with respect to shell was consistent 
throughout the nanofiber(Fig3(d) ). The contrast observed 
between hollow core and intact shell of nanofibers in TEM 
arises due to variable electron beam diffraction. Similarly, in 
the case of type I nanofibers, fiber diameter increased from 
118±4 nm to 141±5 nm after 24 hours of incubation in 





















Fig. 3 TEM micrograph of type I nanofibers (a) before (b) after 
24 hours incubation in PBS, type II nanofibers (c) before and 
(d) after 24 hours incubation in PBS 
 
2.2 Functional characterization of core-shell nanofibers 
 
Drug entrapment efficiency 
The drug entrapment efficiency for curcumin and 5-FU in type 
I and type II was found to be almost equivalent as same amount 
of drug (i.e. 3.5 wt% of PEO) was supplemented to the polymer 
blend and a similar flow rate was adapted in both the cases. The 
entrapment efficiency of 5-FU was estimated to be 75% ±7% 
and 56%±4% for curcumin. The lower encapsulation efficiency 
is ascribed to polymer loss during electrospinning process and 
partly to limits of curcumin detection by UV-Vis 
spectrophotometer at lower concentrations. 
 
Degree of swelling and weight Loss  
As clearly evident from the TEM micrographs of nanofibers 
(Fig 3(c),(d)) the type II nanofibers undergoes relatively higher 
extent of swelling and dissolution as compared to type I 
nanofibers when incubated in PBS.  This contrasting 
characteristics of type I and type II nanofibers is said to arise 
because of difference in core composition and extent of 
crosslinking. In type II nanofibers the core being PEO alone is 
relatively more permissive to swelling and polymer dissolution 
as compared to the crosslinked core of type I nanofibers. The 
degree of swelling and weight loss calculated for type I and 
type II nanofibers was also in correlation with these 
observations; for type I nanofibers degree of swelling was 
estimated to be 15% and for type II nanofibers and it was found 
to be 34 % at the end of 24 hours of incubation. The role of 
degree of swelling and weight loss (i.e. polymer dissolution) in 
drug release from type I and type II nanofibers has been 
elucidated further in drug release kinetics models described in 
the following discussion.  
 
Contact angle analysis 
The type I and type II nanofibers were hydrophilic nature due 
to inherent hydrophilic nature of base polymers i.e. PEO and 
bPEI.  In spite of their overall hydrophilic nature a considerable 
difference in hydrophilicity was observed due to drug loading 
and crosslinking reaction (Fig 4). The bare type I and type II 
core-shell nanofibers exhibited hydrophilic nature with contact 
angle of 51.9 ±0.64 and 57.8 ±0.92 (Fig4 (a)&(b)). Inclusion 
of 5-FU and curcumin in core and shell of nanofibers increased 
the contact angle to 73.4 ±0.56 and 76.1 ±0.75. The presence 
of hydrophobic curcumin in the nanofiber shell layer has 
rendered slight hydrophobicity to nanofibers (type I and type II) 
and this accounts for the increase in contact angle. Whereas, in 
the case of their crosslinked counterparts a small decline in 
contact angle (i.e. 60.4 ±0.44 and 68.4 ±0.37, respectively) 
observed owing to gluteraldehyde content and gluteraldehyde 




Fig. 4 Contact angle measurement for (a) type I and (b) type II 
bare PEO-PEI core-shell nanofibers; (c) type I and (d) type II  
5-FU and curcumin loaded PEO-PEI core-shell nanofibers; (e) 
type I and (f) type II crosslinked 5-FU and curcumin loaded 
PEO-PEI core-shell nanofibers. 
 
TG Analysis 
As evident from the TG analysis of PEO-PEI nanofibers, 
crosslinked nanofibers have slower degradation profile 
indicating their improved stability as compared to that of 
uncrosslinked nanofibers (Fig 5). The amine group interchain 
covalent linkages generated during crosslinking reaction 
accounts for the improved thermal stability of nanofibers. The 
addition of drugs in the nanofibers shifts the degradation 
temperature by 50ºC towards the lower end[11]. This shift in 
degradation profile between PEO-PEI nanofibers and drug 
loaded nanofibers clearly suggests that curcumin and 5-FU 
molecules are inculcated in between polymer chains and are 
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polymeric matrix. The long chain intermolecular hydrogen 
boding in the polymer is interfered by the presence of drug 
molecules, and the presence of polymer chains around drug 
molecules hinders with the intermolecular hydrogen bonding in 
curcumin molecule. Owing to such polymer chain interferences 
crystalline curcumin is transformed to amorphous form. The 
amorphous nature of curcumin loaded in the polymeric fibers 
improves its dissolution in aqueous solution and thereby 
increases the bioavailability of curcumin.  In general, both 
curcumin and 5-FU degrade in single step in the temperature 
range of  210º-400 ºC and 240º-320 ºC, respectively and this 
also contributes to a certain extent for the difference in 
degradation temperature between drug loaded and bare PEO-
PEI nanofibers[12-14]. The initial mass loss up to 120 ºC is 
said to arise because of loss of remnant moisture and 
crosslinking agent in the fibers. The absence of sharp deflection 
in the TGA spectra indicates that the polymer and drug 




                                                                                 
Fig. 5 TGA analysis of crosslinked and drug loaded nanofibers 
 
XRD analysis 
Bare core-shell PEO-PEI nanofibers and drug (5-FU and 
curcumin) loaded PEO-PEI core-shell nanofibers were analyzed 
by XRD to further elucidate drug physical state (intactness in 
therapeutically active form) and its distribution in the 
electrospun polymer nanofibers.  The PEO-PEI nanofibers gave 
a characteristic semi-crystalline peak of PEO at 2θ = 
23.86˚[15]. The XRD patterns of drug loaded nanofibers also 
depicted a broadened peak at same position (i.e. 2θ = 23.86˚) 
and did not possess crystalline peaks characteristic of 
curcumin[16] and 5-FU[17] (Fig 6). This finding confirms the 
absence of disordered crystalline pockets of drugs and also 
indicates uniform distribution of drugs throughout the polymer 
nanofiber. The amorphous nature of the drug in the nanofibers 
is further established by TG analysis and FTIR analysis. 
 
FTIR analysis 
The PEI molecules present in core-shell nanofiber is covalently 
crosslinked by gluteraldehyde. The two aldehyde groups at the 
ends of gluteraldehyde moiety generate Schiff’s base by 
interacting with two amine groups of bPEI molecule in the 
proximity. The bPEI moiety has 25 % primary amine and 50% 
secondary amine groups, though both can react with 
gluteraldehyde, primary amines have higher reactivity as 
 
 




compared to secondary amines[18, 19]. 
A strong decline in absorbance for free –NH2 stretching 
vibration at 1640 cm-1 was observed for gluteraldehyde treated 
PEO-PEI as compared to PEO-PEI(Fig 6). This difference in 
spectra can be ascribed to reduction of free amine groups of 
PEI moiety as a certain fraction of them are involved in imide 
bond formation in gluteraldehyde mediated crosslinking 
reaction, and thus indicating the completion of reaction (Fig. 
S1). Further, a relative increase in stretching vibration of C=O 
(1566 cm-1) group involved in imide bond also confirms 
introduction of additional imide groups during the crosslinking 
process. The other characteristic peaks of PEO and bPEI (at 
1342 cm-1, 1099 cm-1, 960 cm-1 and 842 cm-1) are retained at 
their respective position in the crosslinked PEO-PEI blend 
indicating the absence of any other polymeric interaction. 


























C=O in primary 
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-bending vibration 
of -CH2 group in PEO
 
Fig. 7 FTIR spectra of PEO- bPEI and crosslinked PEO- bPEI. 
nanofibers. 
 
The slight shift in characteristic curcumin bands at 1426 cm-1  
(C-H bending vibration) and 1510 cm-1 (stretching vibration of 
C-C) in IR spectra of curcumin-PEO blend clearly indicates 
that PEO interferes in intermolecular hydrogen bonding of 
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curcumin (Fig. S2) [20]. The presence of such intermolecular 
hydrogen bonding facilitates in retaining curcumin in 
amorphous state. The amorphous curcumin has been found to 
have improved solubility and bio-distribution in in-vivo 
conditions as compared to its crystalline counterpart. Apart 
from this, FTIR study also confirms absence of covalent 
interaction of 5-FU and curcumin with PEO and PEI as their 




The events of polymer crosslinking and polymer dissolution are 
surface phenomenon which leads to morphological changes in 
nanofibers surface and thus are investigated effectively by 
AFM. As both type I and type II fiber underwent polymer 
dissolution with respect to time of incubation in hydrophilic 
environment, the homogenous surface characteristics of such 
treated samples clearly indicates the extent and uniformity of 
crosslinking reaction (Fig. 9). Type I nanofiber retained their 
structure intact as compared to type II nanofibers after 96 hours 
of incubation in PBS. The selective dissolution of core in type 
II nanofibers was clearly evident from the parallel tracks 
(representing individual fibers) observed in the AFM images 
(Fig. 9(b)). In the case of type I nanofibers irregular depressions 
were observed throughout the nanofiber surface indicating slow 




Fig 9. AFM images of (a) type I and (b) type II nanofibers after 
96 hours incubation in PBS.  
 
2.3 Drug release study 
 
Drug release from crosslinked and un-crosslinked core shell 
nanofibers 
 
To overcome initial burst release of drugs from type I and type 
II nanofibers the polymer were crosslinked to different extent 
by gluteraldehyde vapor and amount of drug released was 
monitored by UV-Vis spectrophotometer after 24 hours 
As shown in Fig 8(a) the percentage drug (5-FU) release from 
type I and type II core-shell nanofiber was observed to decline 
gradually with increase in crosslinking time. Such variation in 
Fig. 8 (a) Effect of crosslinking on 5-FU release from type I and type II nanofibers; (b) 5-FU release profile from type I and type II core- 





(b) (a)  




















ARTICLE RSC Advances 
6 | RSC Advances, 2014, 00, 1-3 This journal is © The Royal Society of Chemistry 2014 
release profile can be attributed to slower dissolution profile of 
cross-linked polymers and thus slower drug diffusion. The 
longer fiber pretreatment with crosslinking agent 
(gluteraldehyde vapors) leads to higher degree of crosslinking 
between the amine groups of bPEI molecules in PEO-PEI 
nanofibers. Thus, degree of crosslinking (i.e. crosslinking time) 
of shell polymer (PEO-PEI) proportionately limits the extent of 
5-FU permeation from core of the nanofibers. Similarly, the 
curcumin entrapped in the crosslinked shell of the nanofibers 
also diffuses out at a slower rate from crosslinked nanofibers as 
compared to un-crosslinked drug loaded nanofibers. 
 The release study establishes that there is clear correlation of 
the crosslinking time with the drug release profile, which 
extends a scope for fine-tuning the drug release profile to 
accomplish different therapeutic dosages in desired time spans. 
In both the variations of fibers (type I and type II), it was 
observed that 2 minutes crosslinking time did not significantly 
influence the release of 5-FU and curcumin from the nanofibers 
Fig 8(a). 
At higher crosslinking time (i.e. greater than 2 minutes), a 
periodic shift in drug release towards the lower percentages was 
observed up to 15 minutes crosslinking time. Thus, the system 
under study has an edge over other drug delivery systems in 
tuning the drug diffusion rate by altering the extent of 
crosslinking. It is at times counter-intuitive to observe that in 
spite introducing crosslinks a slight initial spike in 5-FU release 
profile is observed. The possible explanation for this would be 
hydrophilic nature of core PEO polymer and small size of 5-FU 
which enables it to elute from the fiber with ease. The curcumin 
release profile from type I and type II nanofibers followed a similar 
trend upto 96 hours (Fig 10). Curcumin being loaded in the 
crosslinked nanofiber shell (in the case of type I and type II 
nanofibers) is released gradually without any initial burst phase. It 
was observed that in the case of type II nanofibers, the rate of 
curcumin release was marginally higher than type I. The presence of 
hydrophilic uncrosslinked PEO core in type II nanofibers allows 
greater water permeation and thus leads to slightly higher rate of 





Fig 10. Curcumin release profile from type I and type II core-shell 
nanofibers. 
 
Drug release kinetics for type I and type II nanofibers 
 
The in-vitro release profile of drug loaded type I and type II 
core –shell nanofibers are shown in Fig 8(b). The 5-FU release 
profile from type I and type II core-shell nanofibers exhibited 
distinct release profile with contrasting characteristics. The 
initial phase of 5-FU release from type II nanofibers was 
relatively fast, as only the shell layer of the nanofiber was 
crosslinked and the highly hydrophilic PEO core containing 5-
FU remained un-crosslinked. In contrary to this, both core and 
shell layers of type I nanofibers were cross-linked to different 
extent and thus resulted in controlled and sustained 5-FU 
release profile. In both the cases, two distinct phenomenon 
determine the drug release kinetics, one being the extent of 
solvent penetration and the other being rate of polymer 
dissolution. These two phenomena are said to take place at two 
distinct fronts i.e. diffusion front and erosion front, which 
migrate through the polymer matrix with passage of incubation 
time. In the case of type I nanofibers, the polymer composition 
in core and shell layer is almost same and thus all together it 
acts as a composite system of monolithic polymer blend with 5-
FU loaded in the core. The 5-FU release profile from type I 
nanofibers was closely represented by Korsmeyer-Peppas 
model with exponent (n) value of 0.21(Fig 8(c)). The exponent 
value (< 0.5) clearly indicates Fickian diffusion process which 
arises because of swollen polymer matrix and presence of 
heterogeneous regions of quicker dissolution in the composite 
nanofiber [21]. As evident from the TEM images (Fig3 (d)) of 
type II nanofibers, in the initial phase of incubation, the 
crosslinked shell of nanofibers swells due to permeation of PBS 
into the nanofiber core. The core PEO containing 5-FU 
dissolutes the moment it comes in contact with hydrophilic 
environment and leaches out along with 5-FU by transcending 
across the crosslinked nanofiber shell. 
The above mentioned mechanism clearly correlates with TEM 
images of the type II nanofibers (Fig3(d)) which clearly 
indicates swelling i.e. increase in fiber diameter (Region 1), 
selective dissolution of PEO core (Region 2) and the small 
polymer chains at boundary indicate polymer dissolution 
(Region 3). The presence of uniform gradient in contrast 
between the core and shell in nanofibers also strengthens the 
fact that longer PEO chains in the core diffuse toward the 
boundary of nanofiber shell and start accumulating at the core-
shell interface.  
The kinetics of 5-FU release from type II nanofibers were 
compared with various drug release models to consolidate upon 
the mechanism of drug release. The models considered under 
this study included zero order, first order, Higuchi and 
Korsmeyer-Peppas model[22]. The Korsemeyer Peppas model 
fitted the drug release profile to the closest extent with R2 value 
of 0.95146 (Fig 8(d)). The value of exponent, n was 0.96 
indicating anomalous drug transport involving both polymer 
swelling and Fickian diffusion. These interpretations are well in 
coherence with that observed in TEM images as described 
above. 
The curcumin release kinetics in the case of type I and type II 
nanofibers correlated well with Korsemeyer Peppas model 
governing equation. The fitting curve closely represents the 
curcumin release profile with regression values of 0.982 and 
0.987(Fig 11). The exponent values thus obtained from 
Korsemeyer Peppas model in both the cases (i.e 0.3678 and 
0.3515) confirms Fickian diffusion as the driving mechanism 
for release of curcumin. 
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2.4 Cell viability assay 
 
(a) Cell viability assay at 48 hours  
The IC50 of curcumin and 5-FU against A549 cells was 
determined to be 20 µM and 3.45 µg/mL, respectively by MTT 
cell viability assay. The PEO-PEI nanofibers (type I and type 
II) biocompatibility was clearly established by A549 cell 
viability assay at 96 hours of seeding. In both the cases (type I 
and type II nanofibers) nearly equivalent (i.e. 85% and 90%) 
cell viability was obtained with respect to the control (Fig 
12(a&b)). The anti-proliferative effect of type I and type II drug 
loaded core-shell nanofibers against A549 cells after 48 hours 
were depicted as percentage cell viability in Fig 12(a). The 
A549 cells seeded over core-shell nanofibers loaded with 
curcumin and 5-FU were found to have viability of 15% (type 
II) and 32% (type I). The PEO-PEI nanofibers loaded with 
equivalent amount of either curcumin or 5-FU alone accounted 
for 63% and 48% cell viability by the end of 48 hours. The 
sharp difference in cell viability between cells treated with 
either curcumin or 5-FU alone and equivalent combination of 
both 5-FU and curcumin clearly established their synergistic 
effects.  
At the end of 48 hours, type I and type II nanofibers eluted 
around 3.14 and 3.37 µg/mL of 5-Flurouracil which was almost 
equivalent to IC50 value of 5-FU. Though type I and type II 
core-shell nanofibers eluted almost same amount of curcumin 
and 5-FU by the end of 48 hours there were huge difference in 
cell viability i.e. 32 % and 15% for type I and type II 
nanofibers, respectively. The difference in cell viability is said 
to arise because of difference in release profile between type I 
and type II core shell nanofibers (Fig8 (b)). Type I nanofibers 
releases majority of the drugs in the initial phase much earlier 
as compared to that of type II fibers. Thus, the difference in cell 
viability arises due to difference in duration of A549 cells 
exposure to effective anti-proliferative 5-FU concentration in 
the case of type I and type II nanofibers. To confirm the 
foresaid assumption A549 cells viability was estimated in a 

























(b) Cell viability assay at 96 hours 
 
The PEO-PEI nanofibers loaded with either curcumin or 5-FU 
attained cell viability of 70% and 56%, respectively. As 
observed in cell viability assay after 48 hours, the synergistic 
effects of curcumin and 5-FU were obvious in both type I and 
type II nanofibers by the end of 96 hours also.  The percentage 
viability of A549 cells seeded over type I and type II nanofibers 
after 96 hours was found to be 21% and 23%, respectively (Fig 
12(b)). These results were further correlated with study of 
morphology of cells seeded over type I and type II nanofibers at 
different time points. Such a system can be easily tuned to 
deliver right amount of drug in stipulated time interval, which 
extends a scope for attaining better therapeutic efficacy with 
minimum bystander effects.  
Antiproliferative effects of drug loaded type I and type II 
nanofibers against 5-FU resistant U-87 MG cells was clearly 
evident at both 48 and 96 hours (Fig S4). The fibers being 
loaded with both curcumin and 5-FU could effectively 
overcome the acquired 5-FU resistance of U-87 MG cells. The 
difference in atiproliferative efficacy between type I and type II 
at 48 hours (i.e. 44%) was narrowed down to 34% at the end of 
96 hours. In contrast to the case of A549 cells (where cell 
viability at the end of 96 hours was almost same in the case of 
type I and type II nanofibers at 96 hours) there was 
considerable difference in U-87 MG cells viability at the end of 
96 hours due to 5-FU resistance. Same amount of curcumin was 
released at the end of 96 hours in the case of type I and type II 
nanofibers and considering the fact that U-87 MG is 5-FU 
resistant, the decline in cell viability is said to arise due to 
synergistic activity of 5-FU and curcumin. The curcumin 
release from the fiber could possibly presensitize the U-87 MG 
cells towards 5-FU and thus account for the above mentioned 
observation.  
 
2.5 Study of cell morphology 
(a) AO-EB staining 
 
In order to discriminate between healthy cells, apoptotic cells 
and necrotic cells a combination of dyes, ethidium bromide 














Number of Points 9
Degrees of Freedom 7
Reduced Chi-Sqr 0.8457




Type I a 18.04576 1.50659
Type I b 0.3678 0.02047
Korsmeyer Peppas model














Number of Points 9
Degrees of Freedom 7
Reduced Chi-Sqr 1.19847




Type II a 19.9573 1.18884
b 0.35158 0.0148
Korsmeyer Peppas model
Fig 11: Korsmeyer Peppas model fitting curve for curcumin release profile from (a) type I and (b) type II core-shell nanofibers. 
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Fig 12. (a) A549 cells viability assay (MTT assay) after seeding 
on type I and type II nanofibers at (a) 48 hours and (b) 96 hours. 
*1p- Concentration of 5-FU 2.5 wt% of PEO. **2p- 
Concentration of 5-FU as 3.5 wt% of PEO. 
 
(EB) and acridine orange (AO) were used to stain the treated 
cells. Onset of apoptosis (programmed cell death) in cells is 
associated with characteristic morphological changes, which 
includes membrane blebbing, nuclear fragmentation and 
cytoplasmic constriction [23,24]. Apart from apoptosis another 
mechanism of cells death which is commonly observed is 
necrosis (cell death due to injury or trauma).  
Thus, live cell’s nucleus was excluded from EB stain and 
appeared green owing to the presence of AO alone (Fig 13(a)). 
AO is a cell-permeable, vital dye that intercalates into DNA 
and stains the cell’s nucleus green (under blue filter), EB enters 
specifically into cells with disrupted plasma membrane and 
intercalates with double stranded DNA to appear orange color 
under green filter (Fig 13(e),(i)). Cells in early stage of 
apoptosis appeared bright green with spotted nucleus indicating 




nuclear fragmentation (Fig 13(g)). In the latter phase of 
apoptosis, the cell membrane undergoes blebbing and loses its 
intactness which leaves the cells permeable to EB. As EB stains 
the nucleus, cells in latter stage of apoptosis with compromised 
membrane integrity appear orange in color (Fig 13(d)). 
Apoptosis of A549 cells was observed in both the cases but at 
different time points, type I fibers with quicker release profile 
instigated apoptosis at an earlier stage as compared to type II 
fibers (Fig 13) The difference in number of apoptotic cells 
between type I and type II nanofibers were prominently 
observed up to 48 hours after which, apoptotic cells in both the 
cases (type I and type II) attained equivalent proportion (at 96 
hours) which corroborates well with the equivalent amount of 
drug released at 96 hours from type I and type II nanofibers. 
 
 
(b) RhoB and Hoechst 33342 staining 
 
The morphological changes in cellular components during the 
course of apoptosis could be easily discerned by combination of 
dyes RhoB and Hoechst 33342. RhoB and Hoechst 33342 stain 
cytoplasmic components and nucleus exclusively and thus aid 
in tracking subsequent cascade of apoptotic events in A549 
cells seeded over drug loaded nanofibers (type I and type II) at 
96 hours. The constriction of cytoplasmic volume was 
confirmed by drastic reduction in RhoB stained cytoplasmic 
components with respect to time (Fig 14(b)&(c)). Apart from 
this, the irregular and spotted localization of Hoechst 33342 in 
nucleus further confirmed the event of nuclear fragmentation in 
treated cells, which otherwise stains the nucleus uniformly (Fig 
14(e)&(f))[25].  
In certain apoptotic cells, cytoplasmic stain Rho B stained the 
nucleus, which clearly establishes nuclear membrane disruption 
(Fig 14(b)&(c)) and apoptosis. The auto-fluorescent 
nanofiberous PEO-PEI mats underneath the cells were 
visualized under blue filter to confirm their structural integrity 
during the course of therapeutic study. There was no significant 
morphological variation due to slower dissolution of cross-
linked PEO-PEI shell of nanofibers.   
 
Fig 13. AO/EB stained A549 cells seeded over type I and type II 
nanofibers at different time points (i.e. 4 hours, 12 hours, 48 
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Fig 14. Rhodamine B and Hoechst 33342 stained A549 cells seeded 
over (a)control PEO-PEI  nanofibers; (b) type I nanofibers and (c) 
type II nanofibers; Hoechst 33342 stained nuclei of A549 cells 
seeded over (d)control PEO-PEI  nanofibers (e) type I nanofibers 
and (f) type II nanofibers.  
(b) FE-SEM analysis 
 
The FE-SEM images of A549 cells seeded over control PEO- 
PEI nanofibers clearly indicated that cells retain their 
characteristic morphology and their interaction with the 
polymeric fibers favored cell attachment. The close interface 
between the cells and polymeric fibers also improves delivery 
of 5-FU and curcumin loaded in type I and type II nanofibers. 
The A549 cells seeded over type I and type II nanofibers 
underwent a cascade of morphological changes characteristic of 
apoptosis during the 96 hours incubation period. The Fig 
15(b)&(c) are representative images of A549 cells morphology 
after 96 hours incubation on type I and type II drug loaded 
nanofibers. In both the cases, the events of cytoplasmic 
constriction, membrane blebbing and cell lysis were 
prominently observed, whereas the control fibers (Fig 15(a)) 
were permissive to A549 cells growth and proliferation and 
also retained their characteristic cellular morphology at 96 





This work provides a scope for realizing a drug dose tunable 
nanofiber based drug delivery system by one-step crosslinking 
reaction. This additional flexibility of the PEO-PEI based 
nanofiber in terms of scalable release profile enables it to 
suffice the prerequisites for realizing personalized therapeutics. 
The therapeutic efficacy of two such systems i.e. type I and 
type II core-shell PEO-PEI nanofibers loaded with curcumin 
and 5-FU was evaluated at two different time points to establish 
the claim. The results indicated that though both the fibers were 
loaded with equivalent amount of drugs the cell viability at 48 
hours was different in both the cases owing to the lag in drug 
release profile of type I nanofibers. This viability differences 
were nullified at 96 hours as >90% of the drugs loaded in both 
type I and type II nanofibers were released prior to that time 
point. This work also correlates the extent of polymer 
crosslinking to the drug release kinetics. In addition to altering 
the crosslinking agent concentration, in this work precursor 
polymer concentration is also utilised as an additional factor in 
controlling the extent of crosslinking. Thus, this versatile PEO-
PEI based nanofiberous system can be scaled accordingly to 
deliver right amount of drug to the right place and at right point 
of time (i.e. a characteristic controlled drug delivery system). 
The core-shell PEO-PEI nanofibers loaded with two different 
drugs (5-FU and curcumin) having synergistic antineoplastic 
effects can overcome multiple drug resistance and reduce the 
chances of cancer recurrence. 
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